MT. KISCO, N.Y., Dec. 07, 2016 -- ImmuDyne, Inc. (OTCQB:IMMD) (“Immudyne” or the “Company”), a leader in the development and marketing of OTC health and wellness products addressing large unmet needs, today announced that a Definitive Agreement has been reached with Dr. Lilliana Ramirez to endorse and assist with the development of a new line of skincare products based on Immudyne’s proprietary Yeast Beta Glucan ingredient. The brand, Inate MD, will be launched nationally January 1, 2017.
Dr. Lilliana Ramirez is a practicing, board certified dermatologist with a distinguished track record in medicine and academics. She graduated Magna Cum Laude from the University of Puerto Rico and has received many awards for both her research and the practice of medicine.
“Immudyne is partnering with and associating our brand with yet another highly accomplished dermatologist,” stated Mark McLaughlin, President and CEO of Immudyne.
“I’m very pleased to be working with Immudyne,” said Dr. Ramirez. "The Inate MD skincare line is backed by excellent science and a great management team. I think my patients and consumers across the county will enjoy and benefit from use of the Inate MD product line.”
The Inate MD line will initially be available exclusively online and will consist of a Serum, Moisturizer, Instant Wrinkle Eraser and an optional nutritional supplement to support healthier skin and the human Immune System.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Reliance should not be placed on forward-looking statements because they involve unknown risks, uncertainties and other factors, which are, in some cases, beyond the control of Immudyne. Actual events, performance or results could differ materially from the anticipated events, performance or results expressed or implied by such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
About ImmuDyne, Inc.
lmmuDyne, Inc. (the "Company") is a health and wellness company which develops, manufactures, markets, and sells innovative lifestyle products. The Company's lead products contain its proprietary yeast beta glucans that have been shown through testing and analysis to support the immune system. ImmuDyne also has a majority owned direct marketing division that markets immune support, skincare and hair loss products directly to consumers around the world. All of the Company’s intellectual property is protected by patents and/or trade secrets. Additional information can be found on the web at www.immudyne.com.
Contact: lmmuDyne, Inc. Mark McLaughlin: +1-914-714-8901


RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
UPS and Teamsters Reach Agreement to Limit Driver Severance Program
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 



